David H. Persing, Executive VP, Chief Med/Tech Officer at CEPHEID (CPHD), sold 20,000 shares at $38.56 ($760K) on 2013-09-06, disclosed to the SEC on 2013-09-09.
Scheduled sale ($760k) by Executive VP, Chief Med/Tech Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.43 | 5,000 | $187K | 24.6% |
| 2 | $37.80 | 5,000 | $189K | 24.9% |
| 3 | $38.18 | 5,000 | $191K | 25.1% |
| 4 | $38.56 | 5,000 | $193K | 25.4% |
| Total | $37.99 avg | 20,000 | $760K | 100% |
| Filing → |
| CPHD | SELL | 2014-12-02 | $837K | — | Filing → |
| CPHD | SELL | 2014-12-01 | $4.1M | — | Filing → |
| CPHD | SELL | 2014-11-17 | $273K | — | Filing → |